Comprehensive Stock Comparison
Compare Harmony Biosciences Holdings, Inc. (HRMY) vs Apple Inc. (AAPL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | HRMY | 21.5% revenue growth vs AAPL's 6.4% |
| Value | HRMY | Lower P/E (8.0x vs 31.1x) |
| Quality / Margins | AAPL | 27.0% net margin vs HRMY's 18.3% |
| Stability / Safety | HRMY | Beta 0.55 vs AAPL's 1.28, lower leverage |
| Dividends | AAPL | 0.4% yield; 14-year raise streak; HRMY pays no meaningful dividend |
| Momentum (1Y) | AAPL | +9.7% vs HRMY's -15.7% |
| Efficiency (ROA) | AAPL | 31.1% ROA vs HRMY's 12.5%, ROIC 64.5% vs 59.5% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological disorders. It generates nearly all its revenue from WAKIX — its medication for excessive daytime sleepiness in adult narcolepsy patients — with minimal contributions from other sources. The company's moat comes from its specialized expertise in rare neurological conditions and WAKIX's unique mechanism of action as a first-in-class treatment.
Apple is a technology giant that designs and sells premium consumer electronics — most famously the iPhone — along with related software and services. It generates revenue primarily from hardware sales (roughly 80% of total) and a fast-growing services segment (around 20%) that includes the App Store, subscriptions, and licensing. Its key competitive advantage is a powerful ecosystem that locks users into its hardware, software, and services through seamless integration and high switching costs.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AAPL leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). HRMY leads in 1 (Valuation Metrics). 2 tied.
Financial Metrics (TTM)
AAPL is the larger business by revenue, generating $435.6B annually — 501.6x HRMY's $868M. AAPL is the more profitable business, keeping 27.0% of every revenue dollar as net income compared to HRMY's 18.3%. On growth, HRMY holds the edge at +21.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | HRMYHarmony Bioscienc… | AAPLApple Inc. |
|---|---|---|
| RevenueTrailing 12 months | $868M | $435.6B |
| EBITDAEarnings before interest/tax | $232M | $152.9B |
| Net IncomeAfter-tax profit | $159M | $117.8B |
| Free Cash FlowCash after capex | $0 | $123.3B |
| Gross MarginGross profit ÷ Revenue | +77.2% | +47.3% |
| Operating MarginEBIT ÷ Revenue | +24.0% | +32.4% |
| Net MarginNet income ÷ Revenue | +18.3% | +27.0% |
| FCF MarginFCF ÷ Revenue | +40.1% | +28.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +21.1% | +15.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -55.3% | +18.3% |
Valuation Metrics
At 10.5x trailing earnings, HRMY trades at a 70% valuation discount to AAPL's 35.4x P/E. On an enterprise value basis, HRMY's 3.9x EV/EBITDA is more attractive than AAPL's 27.5x.
| Metric | HRMYHarmony Bioscienc… | AAPLApple Inc. |
|---|---|---|
| Market CapShares × price | $1.6B | $3.88T |
| Enterprise ValueMkt cap + debt − cash | $915M | $3.97T |
| Trailing P/EPrice ÷ TTM EPS | 10.53x | 35.41x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.04x | 31.15x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.98x |
| EV / EBITDAEnterprise value multiple | 3.94x | 27.45x |
| Price / SalesMarket cap ÷ Revenue | 1.90x | 9.33x |
| Price / BookPrice ÷ Book value/share | 1.92x | 53.76x |
| Price / FCFMarket cap ÷ FCF | 4.74x | 39.33x |
Profitability & Efficiency
AAPL delivers a 133.5% return on equity — every $100 of shareholder capital generates $134 in annual profit, vs $18 for HRMY. HRMY carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to AAPL's 1.67x. On the Piotroski fundamental quality scale (0–9), AAPL scores 7/9 vs HRMY's 5/9, reflecting strong financial health.
| Metric | HRMYHarmony Bioscienc… | AAPLApple Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +18.2% | +133.5% |
| ROA (TTM)Return on assets | +12.5% | +31.1% |
| ROICReturn on invested capital | +59.5% | +64.5% |
| ROCEReturn on capital employed | +22.6% | +69.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.02x | 1.67x |
| Net DebtTotal debt minus cash | -$733M | $89.7B |
| Cash & Equiv.Liquid assets | $753M | $33.5B |
| Total DebtShort + long-term debt | $20M | $123.3B |
| Interest CoverageEBIT ÷ Interest expense | 15.43x | — |
Total Returns (with DRIP)
A $10,000 investment in AAPL five years ago would be worth $21,049 today (with dividends reinvested), compared to $7,877 for HRMY. Over the past 12 months, AAPL leads with a +9.7% total return vs HRMY's -15.7%. The 3-year compound annual growth rate (CAGR) favors AAPL at 21.9% vs HRMY's -13.5% — a key indicator of consistent wealth creation.
| Metric | HRMYHarmony Bioscienc… | AAPLApple Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -23.6% | -2.4% |
| 1-Year ReturnPast 12 months | -15.7% | +9.7% |
| 3-Year ReturnCumulative with dividends | -35.2% | +81.2% |
| 5-Year ReturnCumulative with dividends | -21.2% | +110.5% |
| 10-Year ReturnCumulative with dividends | -22.9% | +1027.4% |
| CAGR (3Y)Annualised 3-year return | -13.5% | +21.9% |
Risk & Volatility
HRMY is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than AAPL's 1.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AAPL currently trades 91.5% from its 52-week high vs HRMY's 69.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | HRMYHarmony Bioscienc… | AAPLApple Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.55x | 1.28x |
| 52-Week HighHighest price in past year | $40.87 | $288.61 |
| 52-Week LowLowest price in past year | $25.52 | $169.21 |
| % of 52W HighCurrent price vs 52-week peak | +69.8% | +91.5% |
| RSI (14)Momentum oscillator 0–100 | 31.6 | 57.5 |
| Avg Volume (50D)Average daily shares traded | 517K | 40.9M |
Analyst Outlook
Wall Street rates HRMY as "Buy" and AAPL as "Buy". Consensus price targets imply 68.8% upside for HRMY (target: $48) vs 14.7% for AAPL (target: $303). AAPL is the only dividend payer here at 0.39% yield — a key consideration for income-focused portfolios.
| Metric | HRMYHarmony Bioscienc… | AAPLApple Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $48.17 | $303.11 |
| # AnalystsCovering analysts | 13 | 109 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 14 |
| Dividend / ShareAnnual DPS | — | $1.03 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 20 | Feb 26 | Change |
|---|---|---|---|
| Harmony Biosciences… (HRMY) | 100 | 102.24 | +2.2% |
| Apple Inc. (AAPL) | 100 | 201.23 | +101.2% |
Apple Inc. (AAPL) returned +110% over 5 years vs Harmony Biosciences… (HRMY)'s -21%. A $10,000 investment in AAPL 5 years ago would be worth $21,049 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Harmony Biosciences… (HRMY) | $0.00 | $868M | — |
| Apple Inc. (AAPL) | $215.6B | $416.2B | +93.0% |
Apple Inc.'s revenue grew from $215.6B (2016) to $416.2B (2025) — a 7.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Harmony Biosciences… (HRMY) | -25.4% | 18.3% | +172.1% |
| Apple Inc. (AAPL) | 21.2% | 26.9% | +27.0% |
Apple Inc.'s net margin went from 21% (2016) to 27% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Harmony Biosciences… (HRMY) | 73.5 | 13.8 | -81.2% |
| Apple Inc. (AAPL) | 18.4 | 36.4 | +97.8% |
Harmony Biosciences Holdings, Inc. has traded in a 14x–74x P/E range over 5 years; current trailing P/E is ~11x. Apple Inc. has traded in a 13x–41x P/E range over 9 years; current trailing P/E is ~35x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Harmony Biosciences… (HRMY) | -1.42 | 2.71 | +290.8% |
| Apple Inc. (AAPL) | 2.08 | 7.46 | +258.7% |
Apple Inc.'s EPS grew from $2.08 (2016) to $7.46 (2025) — a 15% CAGR.
Chart 6Free Cash Flow — 5 Years
Harmony Biosciences Holdings, Inc. generated $348M FCF in 2025 (+254% vs 2021). Apple Inc. generated $99B FCF in 2025 (+6% vs 2021).
HRMY vs AAPL: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is HRMY or AAPL a better buy right now?
Harmony Biosciences Holdings, Inc. (HRMY) offers the better valuation at 10.5x trailing P/E (8.0x forward), making it the more compelling value choice. Analysts rate Harmony Biosciences Holdings, Inc. (HRMY) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HRMY or AAPL?
On trailing P/E, Harmony Biosciences Holdings, Inc. (HRMY) is the cheapest at 10.5x versus Apple Inc. at 35.4x. On forward P/E, Harmony Biosciences Holdings, Inc. is actually cheaper at 8.0x.
03Which is the better long-term investment — HRMY or AAPL?
Over the past 5 years, Apple Inc. (AAPL) delivered a total return of +110.5%, compared to -21.2% for Harmony Biosciences Holdings, Inc. (HRMY). A $10,000 investment in AAPL five years ago would be worth approximately $21K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AAPL returned +1027% versus HRMY's -22.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HRMY or AAPL?
By beta (market sensitivity over 5 years), Harmony Biosciences Holdings, Inc. (HRMY) is the lower-risk stock at 0.55β versus Apple Inc.'s 1.28β — meaning AAPL is approximately 131% more volatile than HRMY relative to the S&P 500. On balance sheet safety, Harmony Biosciences Holdings, Inc. (HRMY) carries a lower debt/equity ratio of 2% versus 167% for Apple Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — HRMY or AAPL?
Apple Inc. (AAPL) is the more profitable company, earning 26.9% net margin versus 18.3% for Harmony Biosciences Holdings, Inc. — meaning it keeps 26.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AAPL leads at 32.0% versus 24.0% for HRMY. At the gross margin level — before operating expenses — HRMY leads at 77.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is HRMY or AAPL more undervalued right now?
On forward earnings alone, Harmony Biosciences Holdings, Inc. (HRMY) trades at 8.0x forward P/E versus 31.1x for Apple Inc. — 23.1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HRMY: 68.8% to $48.17.
07Which pays a better dividend — HRMY or AAPL?
In this comparison, AAPL (0.4% yield) pays a dividend. HRMY does not pay a meaningful dividend and should not be held primarily for income.
08Is HRMY or AAPL better for a retirement portfolio?
For long-horizon retirement investors, Apple Inc. (AAPL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.28), +1027% 10Y return). Both have compounded well over 10 years (AAPL: +1027%, HRMY: -22.9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between HRMY and AAPL?
These companies operate in different sectors (HRMY (Healthcare) and AAPL (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced. In terms of investment character: HRMY is a small-cap deep-value stock; AAPL is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.